Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Asset Writedowns and Impairment (2023 - 2025)

Ptc Therapeutics (PTCT) has 3 years of Asset Writedowns and Impairment data on record, last reported at $500000.0 in Q4 2025.

  • For Q4 2025, Asset Writedowns and Impairment fell 99.69% year-over-year to $500000.0; the TTM value through Dec 2025 reached $161.4 million, down 57.37%, while the annual FY2025 figure was $1.0 million, 75.14% down from the prior year.
  • Asset Writedowns and Impairment reached $500000.0 in Q4 2025 per PTCT's latest filing, up from $100000.0 in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $217.8 million in Q2 2023 and bottomed at $100000.0 in Q2 2025.
  • Average Asset Writedowns and Impairment over 3 years is $75.8 million, with a median of $1.3 million recorded in 2024.
  • The widest YoY moves for Asset Writedowns and Impairment: up 99.69% in 2025, down 99.69% in 2025.
  • A 3-year view of Asset Writedowns and Impairment shows it stood at $217.8 million in 2023, then decreased by 26.77% to $159.5 million in 2024, then tumbled by 99.69% to $500000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Asset Writedowns and Impairment were $500000.0 in Q4 2025, $100000.0 in Q2 2025, and $159.5 million in Q4 2024.